Idalopirdine Plus Cholinesterase Inhibitors Doesn’t Help Alzheimer’s Patients, Study Finds

Idalopirdine Plus Cholinesterase Inhibitors Doesn’t Help Alzheimer’s Patients, Study Finds
Three Phase 3 clinical studies have failed to reproduce previously reported benefits of adding investigational idalopirdine to a background therapy of cholinesterase inhibitors. The three randomized trials detected no improvements in cognition among mild to moderate Alzheimer's disease patients treated this way. The study, “Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease,” appeared in JAMA. To date, the U.S. Food and Drug Administration (FDA) has approved only two classes of medications for Alzheimer's: cholinesterase
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *